SEARCH OUR PRODUCT CATALOG

KCNK5-RUNX2 Fusion FISH Probe

The KCNK5-RUNX2 Fusion FISH Probe is used to confirm a fusion of the KCNK5 and RUNX2 genes. The fusion of the KCNK5 and RUNX2 genes has been associated with Kidney Renal Papillary Cell Carcinoma. These probes are FISH confirmed on normal peripheral blood in both interphase nuclei and metaphase spreads before shipment. Typical turnaround time for this product is 7-14 days after purchase.

** This product is for in vitro and research use only. This product is not intended for diagnostic use. Please note that both genes fall on the same chromosome and inter-chromosomal detection may be difficult to detect depending on the genes proximity to one another. Please consult our support staff before ordering this product to ensure that the probe can be designed to meet your specific needs.

Turnaround Time: 7-10 Business Days    Shipping Time: 1-2 Day Expedited Shipping

SKU Test Kits Buffer Dye Color Order Now
KCNK5-RUNX2-20-ORGR  (Standard Design) 20 (40 μL) 200 μL
KCNK5-RUNX2-20-RERE 20 (40 μL) 200 μL
KCNK5-RUNX2-20-REOR 20 (40 μL) 200 μL
KCNK5-RUNX2-20-REGO 20 (40 μL) 200 μL
KCNK5-RUNX2-20-REGR 20 (40 μL) 200 μL
KCNK5-RUNX2-20-REAQ 20 (40 μL) 200 μL
KCNK5-RUNX2-20-ORRE 20 (40 μL) 200 μL
KCNK5-RUNX2-20-OROR 20 (40 μL) 200 μL
KCNK5-RUNX2-20-ORGO 20 (40 μL) 200 μL
KCNK5-RUNX2-20-ORAQ 20 (40 μL) 200 μL
KCNK5-RUNX2-20-GORE 20 (40 μL) 200 μL
KCNK5-RUNX2-20-GOOR 20 (40 μL) 200 μL
KCNK5-RUNX2-20-GOGO 20 (40 μL) 200 μL
KCNK5-RUNX2-20-GOGR 20 (40 μL) 200 μL
KCNK5-RUNX2-20-GOAQ 20 (40 μL) 200 μL
KCNK5-RUNX2-20-GRRE 20 (40 μL) 200 μL
KCNK5-RUNX2-20-GROR 20 (40 μL) 200 μL
KCNK5-RUNX2-20-GRGO 20 (40 μL) 200 μL
KCNK5-RUNX2-20-GRGR 20 (40 μL) 200 μL
KCNK5-RUNX2-20-GRAQ 20 (40 μL) 200 μL
KCNK5-RUNX2-20-AQRE 20 (40 μL) 200 μL
KCNK5-RUNX2-20-AQOR 20 (40 μL) 200 μL
KCNK5-RUNX2-20-AQGO 20 (40 μL) 200 μL
KCNK5-RUNX2-20-AQGR 20 (40 μL) 200 μL
KCNK5-RUNX2-20-AQAQ 20 (40 μL) 200 μL

RUNX2 Gene Summary

This gene is a member of the RUNX family of transcription factors and encodes a nuclear protein with an Runt DNA-binding domain. This protein is essential for osteoblastic differentiation and skeletal morphogenesis and acts as a scaffold for nucleic acids and regulatory factors involved in skeletal gene expression. The protein can bind DNA both as a monomer or, with more affinity, as a subunit of a heterodimeric complex. Two regions of potential trinucleotide repeat expansions are present in the N-terminal region of the encoded protein, and these and other mutations in this gene have been associated with the bone development disorder cleidocranial dysplasia (CCD). Transcript variants that encode different protein isoforms result from the use of alternate promoters as well as alternate splicing. [provided by RefSeq, Jul 2016]

Gene Name: Runt Related Transcription Factor 2

Chromosome: CHR6: 45296053 -45518819

Locus: 6p21.1

KCNK5 Gene Summary

This gene encodes one of the members of the superfamily of potassium channel proteins containing two pore-forming P domains. The message for this gene is mainly expressed in the cortical distal tubules and collecting ducts of the kidney. The protein is highly sensitive to external pH and this, in combination with its expression pattern, suggests it may play an important role in renal potassium transport. [provided by RefSeq, Jul 2008]

Gene Name: Potassium Two Pore Domain Channel Subfamily K Member 5

Chromosome: CHR6: 39156746 -39197251

Locus: 6p21.2

Gene Diseases

The KCNK5 RUNX2 Fusion has been associated with the following diseases:

Disease Name
Kidney Renal Papillary Cell Carcinoma

FISH Probe Protocols

Protocol, Procedure, or Form Name Last Modified Download

Lineage-specific RUNX2 super-enhancer activates MYC and promotes the development of blastic plasmacytoid dendritic cell neoplasm

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a particularly aggressive acute leukemia. BPDCN patients display significantly higher levels of RUNX2 compared to other leukemia patients, due to the RUNX2 super-enhancers harbored by BPDCN cells. Because MYC translocations are also recurrent abnormalities in BPDCN, the team wanted to determine whether RUNX2 super-enhancers also upregulate MYC expression in these tumors. Empire Genomics' RUNX2 probe was used to detect RUNX2 amplification in a series of BPDCNs. Results demonstrated that RUNX2 super-enhancers are in fact hijacked to activate MYC via t(6,8) in BPDCN.